| Entry |
|
|---|
| Name |
Nicardipine hydrochloride (JP18/USAN);
Cardene (TN) |
|---|
| Product |
|
|---|
| Generic |
NICARDIPINE HYDROCHLORIDE (ANI Pharmaceuticals), NICARDIPINE HYDROCHLORIDE (American Regent), NICARDIPINE HYDROCHLORIDE (AuroMedics Pharma LLC), NICARDIPINE HYDROCHLORIDE (AuroMedics Pharma LLC), NICARDIPINE HYDROCHLORIDE (Burel Pharmaceuticals), NICARDIPINE HYDROCHLORIDE (Civica), NICARDIPINE HYDROCHLORIDE (Epic Pharma), NICARDIPINE HYDROCHLORIDE (Glenmark Pharmaceuticals), NICARDIPINE HYDROCHLORIDE (Micro Labs Limited), NICARDIPINE HYDROCHLORIDE (PuraCap Laboratories LLC dba Blu Pharmaceuticals), NICARDIPINE HYDROCHLORIDE (SQUARE PHARMACEUTICALS LIMITED), NICARDIPINE HYDROCHLORIDE (Wockhardt USA LLC.) |
|---|
| Formula |
C26H29N3O6. HCl
|
|---|
| Exact mass |
515.1823
|
|---|
| Mol weight |
515.9859
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG03231 Antihypertensive
DG01928 Dihydropyridine calcium channel blocker
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2149 |
| Product (DG00323): | D00617<JP/US> |
|
|---|
| Efficacy |
Antihypertensive, Vasodilator, Calcium channel blocker |
|---|
| Disease |
|
|---|
| Comment |
Dihydropyridine derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C08 CALCIUM CHANNEL BLOCKERS
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08CA Dihydropyridine derivatives
C08CA04 Nicardipine
D00617 Nicardipine hydrochloride (JP18/USAN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Calcium Channel Blocking Agents, Dihydropyridines
Nicardipine
D00617 Nicardipine hydrochloride (JP18/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
214 Antihypertensives
2149 Others
D00617 Nicardipine hydrochloride (JP18/USAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG00323 Nicardipine
D00617 Nicardipine hydrochloride
DG03231 Antihypertensive
DG01928 Dihydropyridine calcium channel blocker
DG00323 Nicardipine
D00617 Nicardipine hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00323 Nicardipine
D00617 Nicardipine hydrochloride
Drug classes [BR:br08332]
Cardiovascular agent
DG01928 Dihydropyridine calcium channel blocker
D00617 Nicardipine hydrochloride
DG03231 Antihypertensive
D00617 Nicardipine hydrochloride
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Calcium channels
CACNA1-L
D00617 Nicardipine hydrochloride (JP18/USAN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00617 Nicardipine hydrochloride
D00617 Nicardipine hydrochloride injection
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00617
Drug groups [BR:br08330]
Cardiovascular agent
DG01575 Calcium channel blocker
DG01496 Calcium channel L type blocker
DG00323 Nicardipine
DG03231 Antihypertensive
DG01928 Dihydropyridine calcium channel blocker
DG00323 Nicardipine
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00323 Nicardipine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 36
1 C1y C 19.9164 -15.4819
2 C8y C 19.9164 -16.8638
3 C2y C 21.1058 -14.7939
4 C2y C 18.7210 -14.7939
5 C8x C 21.1175 -17.5519
6 C8x C 18.7327 -17.5519
7 C2y C 21.1058 -13.4118
8 C7a C 22.3071 -15.4819
9 C2y C 18.7210 -13.4118
10 C7a C 17.5256 -15.4877
11 C8y C 21.1234 -18.9280
12 C8x C 18.7327 -18.9339
13 N1x N 19.9164 -12.7238
14 C1a C 22.3071 -12.7238
15 O7a O 23.5024 -14.7939
16 O6a O 22.3071 -16.8638
17 C1a C 17.5256 -12.7238
18 O7a O 16.3244 -14.7939
19 O6a O 17.5256 -16.8638
20 C8x C 19.9280 -19.6220
21 N2b N 22.3245 -19.6220 #+
22 C1b C 24.6976 -15.4819
23 C1a C 15.1290 -15.4877
24 O3a O 23.8231 -18.6598
25 O3a O 22.3536 -21.3130 #-
26 C1b C 25.8989 -14.7880
27 N1c N 27.0884 -15.4819
28 C1b C 28.2837 -14.7880
29 C1a C 27.0943 -16.8638
30 C8y C 29.4791 -15.4760
31 C8x C 29.4791 -16.8581
32 C8x C 30.6804 -14.7880
33 C8x C 30.6804 -17.5461
34 C8x C 31.8757 -15.4760
35 C8x C 31.8757 -16.8581
36 X Cl 35.0069 -16.2400
BOND 37
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 2
6 3 7 2
7 3 8 1
8 4 9 2
9 4 10 1
10 5 11 2
11 6 12 1
12 7 13 1
13 7 14 1
14 8 15 1
15 8 16 2
16 9 17 1
17 10 18 1
18 10 19 2
19 11 20 1
20 11 21 1
21 15 22 1
22 18 23 1
23 21 24 2
24 21 25 1
25 22 26 1
26 26 27 1
27 27 28 1
28 27 29 1
29 28 30 1
30 30 31 2
31 30 32 1
32 31 33 1
33 32 34 2
34 33 35 2
35 9 13 1
36 12 20 2
37 34 35 1
|
|---|
